JP2010525025A5 - - Google Patents

Download PDF

Info

Publication number
JP2010525025A5
JP2010525025A5 JP2010504692A JP2010504692A JP2010525025A5 JP 2010525025 A5 JP2010525025 A5 JP 2010525025A5 JP 2010504692 A JP2010504692 A JP 2010504692A JP 2010504692 A JP2010504692 A JP 2010504692A JP 2010525025 A5 JP2010525025 A5 JP 2010525025A5
Authority
JP
Japan
Prior art keywords
phenyl
compound
pyrimidin
substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010504692A
Other languages
English (en)
Japanese (ja)
Other versions
JP5566880B2 (ja
JP2010525025A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/055017 external-priority patent/WO2008129080A1/en
Publication of JP2010525025A publication Critical patent/JP2010525025A/ja
Publication of JP2010525025A5 publication Critical patent/JP2010525025A5/ja
Application granted granted Critical
Publication of JP5566880B2 publication Critical patent/JP5566880B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010504692A 2007-04-24 2008-04-24 プロテインキナーゼの阻害剤としての4,6−二置換アミノピリミジン誘導体 Expired - Fee Related JP5566880B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPPCT/EP2007/003608 2007-04-24
EP2007003608 2007-04-24
EP07106951 2007-04-25
EP07106951.2 2007-04-25
PCT/EP2008/055017 WO2008129080A1 (en) 2007-04-24 2008-04-24 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases

Publications (3)

Publication Number Publication Date
JP2010525025A JP2010525025A (ja) 2010-07-22
JP2010525025A5 true JP2010525025A5 (cg-RX-API-DMAC7.html) 2011-06-23
JP5566880B2 JP5566880B2 (ja) 2014-08-06

Family

ID=39745232

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010504692A Expired - Fee Related JP5566880B2 (ja) 2007-04-24 2008-04-24 プロテインキナーゼの阻害剤としての4,6−二置換アミノピリミジン誘導体

Country Status (4)

Country Link
US (2) US8507498B2 (cg-RX-API-DMAC7.html)
EP (1) EP2137166B1 (cg-RX-API-DMAC7.html)
JP (1) JP5566880B2 (cg-RX-API-DMAC7.html)
WO (1) WO2008129080A1 (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1692113B1 (en) 2003-11-14 2017-09-27 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
AU2011231975B2 (en) * 2010-03-22 2014-07-03 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted triazine derivatives
CA2826464C (en) 2011-03-02 2020-07-28 Lead Discovery Center Gmbh Pharmaceutically active disubstituted triazine derivatives
EP2681193B1 (en) * 2011-03-02 2016-01-06 Lead Discovery Center GmbH Pharmaceutically active disubstituted pyridine derivatives
JP5912172B2 (ja) 2011-04-19 2016-04-27 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換された4−アリール−n−フェニル−1,3,5−トリアジン−2−アミン
EP2527332A1 (en) 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
ES2587284T3 (es) * 2011-09-16 2016-10-21 Bayer Intellectual Property Gmbh 5-Fluoro-pirimidinas 2,4-disustituidas como inhibidores selectivos de CDK9
CN103930399B (zh) 2011-09-16 2016-03-16 拜耳知识产权有限责任公司 包含亚氨基亚磺酰基的二取代的5-氟嘧啶衍生物
US9498471B2 (en) 2011-10-20 2016-11-22 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
EP2887943B1 (en) * 2012-08-23 2017-12-06 Virostatics Srl Novel 4,6-disubstituted aminopyrimidine derivatives
CA2888383A1 (en) * 2012-10-18 2014-04-24 Bayer Pharma Aktiengesellschaft N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
HK1213890A1 (zh) 2012-10-18 2016-07-15 Bayer Pharma Aktiengesellschaft 含碸基团的4-(邻)-氟苯基-5-氟嘧啶-2-基胺
CN104854091B (zh) 2012-10-18 2018-04-03 拜耳药业股份公司 含砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物
ES2622583T3 (es) * 2012-11-15 2017-07-06 Bayer Pharma Aktiengesellschaft 4-(Orto)-fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina
TW201418243A (zh) * 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
MX374333B (es) * 2012-11-15 2025-03-06 Bayer Pharma AG Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina.
CN105492438B (zh) 2013-07-04 2018-08-07 拜耳医药股份有限公司 磺亚胺取代的5-氟-n-(吡啶-2-基)吡啶-2-胺衍生物以及其作为cdk9激酶抑制剂的用途
EP3650023A1 (en) * 2013-10-04 2020-05-13 Aptose Biosciences Inc. Compositions for treating cancers
AR098394A1 (es) 2013-11-25 2016-05-26 Lilly Co Eli Inhibidores de dgat2 (diacilglicerol o-aciltransferasa 2)
CN106232596A (zh) 2014-03-13 2016-12-14 拜耳医药股份有限公司 含有砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物
CN106414412B (zh) 2014-04-01 2019-06-21 拜耳医药股份有限公司 含有磺酰二亚胺基团的二取代的5-氟嘧啶衍生物
WO2015153870A1 (en) 2014-04-04 2015-10-08 Memorial Sloan-Kettering Cancer Center Method and kits for identifying of cdk9 inhibitors for the treatment of cancer
CR20160471A (es) 2014-04-11 2016-12-21 Bayer Pharma AG Compuestos novedosos macrocíclicos
JP6930913B2 (ja) 2014-10-14 2021-09-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California 炎症を阻害するためのcdk9及びbrd4阻害剤の使用法
CA2964683A1 (en) 2014-10-16 2016-04-21 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group
WO2016059086A1 (en) 2014-10-16 2016-04-21 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group
WO2016150893A1 (en) 2015-03-24 2016-09-29 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating multiple myeloma
CN107427520A (zh) 2015-03-24 2017-12-01 拜耳医药股份有限公司 4‑(4‑氟‑2‑甲氧基苯基)‑n‑{3‑[(s‑甲基磺酰亚氨基)甲基]苯基}‑1,3,5‑三嗪‑2‑胺用于治疗淋巴瘤的用途
WO2016150902A1 (en) 2015-03-24 2016-09-29 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating gastric cancers
LT3313838T (lt) 2015-06-29 2019-06-10 Astrazeneca Ab Policikliniai amido dariniai, kaip cdk9 slopikliai
EP3356373B1 (en) 2015-09-29 2020-02-19 Bayer Pharma Aktiengesellschaft Novel macrocyclic sulfondiimine compounds
CN108368129B (zh) 2015-10-08 2021-08-17 拜耳医药股份有限公司 改性大环化合物
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
BR112019000796A2 (pt) 2016-07-16 2019-04-24 Florida State University Research Foundation, Inc. compostos e métodos para tratamento e prevenção da infecção flavivirus
US11254690B2 (en) 2017-03-28 2022-02-22 Bayer Pharma Aktiengesellschaft PTEFb inhibiting macrocyclic compounds
CA3057891A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
WO2019075011A1 (en) 2017-10-10 2019-04-18 Florida State University Research Foundation, Inc. EMETIC COMPOUNDS FOR THE TREATMENT AND PREVENTION OF FLAVIVIRUS INFECTION
AU2018360477A1 (en) 2017-10-30 2020-06-04 Aptose Biosciences Inc. Aryl imidazoles for the treatment of cancer
MA51820A (fr) 2018-02-13 2021-05-19 Bayer Ag Utilisation de 5-fluoro-4-(4-fluoro-2-méthoxyphényl)-n-(4-[(s-méthylsulfonimidoyl)méthyl]pyridin-2-yl)pyridin-2-amine pour traiter un lymphome diffus à grandes cellules b
WO2020235672A1 (ja) * 2019-05-23 2020-11-26 国立大学法人京都大学 アルツハイマー病のための医薬組成物
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9319568D0 (en) 1993-09-22 1993-11-10 Euro Celtique Sa Pharmaceutical compositions and usages
CA2401748A1 (en) 2000-03-29 2001-10-04 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
ES2292753T4 (es) 2001-03-29 2009-02-16 Vertex Pharmaceuticals Incorporated Inhibidores de quinasas n-terminales c-jun (jnk) y otras proteina quinasas.
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US20040106647A1 (en) 2002-06-28 2004-06-03 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
US7576085B2 (en) 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
US7419984B2 (en) * 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
CA2503715A1 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Kinase inhibitors
CN1826328A (zh) 2003-07-22 2006-08-30 神经能质公司 经取代的吡啶-2-基胺类似物
EP1648875A1 (en) 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
US8084457B2 (en) 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
US20080242681A1 (en) 2004-01-22 2008-10-02 Altana Pharma Ag N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors
TW200614993A (en) 2004-06-11 2006-05-16 Akzo Nobel Nv 4-phenyl-pyrimidine-2-carbonitrile derivatives
EP1901747A2 (en) 2005-05-25 2008-03-26 Ingenium Pharmaceuticals AG Pyrimidine-based cdk inhibitors for treating pain
JP5693951B2 (ja) * 2007-04-24 2015-04-01 アストラゼネカ エービー プロテインキナーゼの阻害剤
EP2137165B1 (en) * 2007-04-24 2013-04-24 Ingenium Pharmaceuticals GmbH Inhibitors of protein kinases
JP5566879B2 (ja) * 2007-04-24 2014-08-06 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤

Similar Documents

Publication Publication Date Title
JP2010525025A5 (cg-RX-API-DMAC7.html)
JP2010525023A5 (cg-RX-API-DMAC7.html)
JP2011502956A5 (cg-RX-API-DMAC7.html)
JP2004536814A5 (cg-RX-API-DMAC7.html)
JP2013523710A5 (cg-RX-API-DMAC7.html)
HRP20241159T1 (hr) Heterociklički agonisti za glp-1
JP2020023577A5 (cg-RX-API-DMAC7.html)
JP2010512337A5 (cg-RX-API-DMAC7.html)
PT1979331E (pt) Compostos de amina trissubstituída como inibidores da proteína de transferência de éster de colesterilo
KR20090128478A (ko) 페닐 아미노 피리미딘 화합물 및 이의 용도
RU2016115803A (ru) Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний
HUT67636A (en) New sulfonylamino-pyrimidines and pharmaceutical compositions containing them
SI2797918T1 (en) Bromodomain inhibitors
JP2020529405A5 (cg-RX-API-DMAC7.html)
RU2007101236A (ru) Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей
JP2011519854A5 (cg-RX-API-DMAC7.html)
RU2507205C2 (ru) Арилциклогексилэфиры дигидротетраазабензоазуленов для применения в качестве антагонистов рецептора вазопрессина v1a
RU2017104918A (ru) СОЛЬ ПРИСОЕДИНЕНИЯ КИСЛОТЫ СОЕДИНЕНИЯ, ИНГИБИРУЮЩЕГО Trk
JP2011523646A5 (cg-RX-API-DMAC7.html)
JP2016512844A5 (cg-RX-API-DMAC7.html)
JP2007500179A5 (cg-RX-API-DMAC7.html)
JP2017515836A5 (cg-RX-API-DMAC7.html)
ME02763B (me) Derivati bipirazola kao inhibitori jak
RU2009133846A (ru) Новые производные гидантоина в качестве ингибиторов металлопротеиназ
JP2013510876A5 (cg-RX-API-DMAC7.html)